Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial.

Medicine (Baltimore) · 2015 · PMC5291631 · PMID 26717390

Europe PMC DOI

hedged sentence

0.0610

closest p · 1.2× alpha

0.0610

boldest claim

The sentences

did not reach statistical significanceP = 0.061so close (0.05 < p ≤ 0.1)

The number of filters used every 24 hours during CRRT was lower in the NM group than in the NA group (1.4 ± 1.2 versus 2.4 ± 2.2), although this difference did not reach statistical significance ( P = 0.061).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.